The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

A new study indicates that certain GLP-1 weight-loss drugs can help ... Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs receive a prescription for it, according to a new study from ... like peptide-1 (GLP-1) agonists are ...

Carly Johnson of Momentum Worldwide says the results of a new survey show ... shift in behaviors to come. In a recent study, we found that over half of respondents were interested in using a GLP-1 ...

The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

The study highlighted ... about how well these drugs work," she said. "With current studies showing conflicting results on mood disorders and the use of GLP-1 drugs, it’s important for all ...

First-generation GLP-1 drugs like liraglutide (Saxenda) and exenatide (Byetta) were associated with a 41% lower risk of ...